Ester Falconer

Ester Falconer

Auto-generated profile, based on publicly available information

Ester Falconer

AbCellera Biologics Inc., Vancouver, BC V5Y 0A1, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2022 in Cell Reports
Verified
Journal Article
Open access
KWKathryn Westendorf
Kathryn Westendorf
SŽStefanie Žentelis
Stefanie Žentelis
LWLingshu Wang
Lingshu Wang
DFDenisa Foster
Denisa Foster
PVPeter Vaillancourt
Peter Vaillancourt
BBBryan C. Barnhart
Bryan C. Barnhart
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 (COVID-19) when administered early. However, SARS-CoV-2 variants of concern (VOCs) have negatively affected therapeutic use of some authorized mAbs. Using a high-throughput B cell screening pipeline, we isolated LY-CoV1404 (bebtelovimab), a highly potent SARS-CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody. LY-CoV1404 potently neutralizes authentic SARS-CoV-2, B.1.1.7, B.1.351, and B.1.617.2. In pseudovirus neutralization studies, LY-CoV1404 potently neutralizes variants, including B.1.1.7, B.1.351, B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, B.1.1.529, and the BA.2 subvariant. Structural analysis reveals that the contact residues of the LY-CoV1404 epitope are highly conserved, except for N439 and N501. The binding and neutralizing activity of LY-CoV1404 is unaffected by the most common mutations at these positions (N439K and N501Y). The broad and potent neutralization activity and the relatively conserved epitope suggest that LY-CoV1404 has the potential to be an effective therapeutic agent to treat all known variants.

12 May 2021 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
BJBryan E. Jones
Bryan E. Jones
PBPatricia Brown-Augsburger
Patricia Brown-Augsburger
KCKizzmekia S. Corbett
Kizzmekia S. Corbett
KWKathryn Westendorf
Kathryn Westendorf
JDJulian Davies
Julian Davies
EFEster Falconer
Ester Falconer
LY-CoV555, a SARS-CoV-2 spike protein–specific antibody, neutralizes SARS-CoV-2 and protects the airways of nonhuman primates against infection.

16 October 2021 in Cell Reports
Verified
Journal Article
Open access
CHChing-Lin Hsieh
Ching-Lin Hsieh
AWAnne P. Werner
Anne P. Werner
SLSarah R. Leist
Sarah R. Leist
LSLaura J. Stevens
Laura J. Stevens
EFEster Falconer
Ester Falconer
JMJason McLellan
Jason McLellan
Current coronavirus (CoV) vaccines primarily target immunodominant epitopes in the S1 subunit, which are poorly conserved and susceptible to escape mutations, thus threatening vaccine efficacy. Here, we use structure-guided protein engineering to remove the S1 subunit from the Middle East respiratory syndrome (MERS)-CoV spike (S) glycoprotein and develop stabilized stem (SS) antigens. Vaccination with MERS SS elicits cross-reactive β-CoV antibody responses and protects mice against lethal MERS-CoV challenge. High-throughput screening of antibody-secreting cells from MERS SS-immunized mice led to the discovery of a panel of cross-reactive monoclonal antibodies. Among them, antibody IgG22 binds with high affinity to both MERS-CoV and severe acute respiratory syndrome (SARS)-CoV-2 S proteins, and a combination of electron microscopy and crystal structures localizes the epitope to a conserved coiled-coil region in the S2 subunit. Passive transfer of IgG22 protects mice against both MERS-CoV and SARS-CoV-2 challenge. Collectively, these results provide a proof of principle for cross-reactive CoV antibodies and inform the development of pan-CoV vaccines and therapeutic antibodies.

1 October 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
BJBryan E. Jones
Bryan E. Jones
PBPatricia L. Brown-Augsburger
Patricia L. Brown-Augsburger
KCKizzmekia S. Corbett
Kizzmekia S. Corbett
KWKathryn Westerndorf
Kathryn Westerndorf
JDJulian Davies
Julian Davies
EFEster Falconer
Ester Falconer
SARS-CoV-2 poses a public health threat for which therapeutic agents are urgently needed. Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led to the identification of LY-CoV555, a potent anti-spike neutralizing antibody from a convalescent COVID-19 patient. Biochemical, structural, and functional characterization revealed high-affinity binding to the receptor-binding domain, ACE2 binding inhibition, and potent neutralizing activity. In a rhesus macaque challenge model, prophylaxis doses as low as 2.5 mg/kg reduced viral replication in the upper and lower respiratory tract. These data demonstrate that high-throughput screening can lead to the identification of a potent antiviral antibody that protects against SARS-CoV-2 infection. One Sentence Summary: LY-CoV555, an anti-spike antibody derived from a convalescent COVID-19 patient, potently neutralizes SARS-CoV-2 and protects the upper and lower airways of non-human primates against SARS-CoV-2 infection.